Gardasil Anal Cancer Indication: CBER Has No Concerns, But What Will ACIP Think?
This article was originally published in The Pink Sheet Daily
Executive Summary
Nov. 17 session is product's third before an FDA advisory committee, but review by CDC's immunization practices panel may be key for utilization and reimbursement.
You may also be interested in...
Gardasil Getting Pediatric Safety Review
Despite the political noise around the human papillomavirus vaccine, there do not seem to be major new pediatric safety concerns for the Pediatric Advisory Committee to discuss as it reviews Gardasil and 14 other products.
Gardasil Anal Cancer Indication To Face FDA Advisory Committee Scrutiny
Supplemental application filed earlier this year is part of Merck's strategy to broaden use of the HPV vaccine, although its bid to expand the label to women ages 27-45 has thus far been blocked by the agency.
Gardasil For Males Gets FDA OK; Next Up, Cost-Effectiveness Questions
Merck's Gardasil human papillomavirus vaccine is headed back for a key review by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices on Oct. 21 with FDA's safety and efficacy approval in hand